1. Home
  2. ARTL vs SYTA Comparison

ARTL vs SYTA Comparison

Compare ARTL & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • SYTA
  • Stock Information
  • Founded
  • ARTL 2011
  • SYTA N/A
  • Country
  • ARTL United States
  • SYTA Canada
  • Employees
  • ARTL N/A
  • SYTA N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • SYTA Telecommunications Equipment
  • Sector
  • ARTL Health Care
  • SYTA Telecommunications
  • Exchange
  • ARTL Nasdaq
  • SYTA Nasdaq
  • Market Cap
  • ARTL 3.8M
  • SYTA 3.1M
  • IPO Year
  • ARTL N/A
  • SYTA 2020
  • Fundamental
  • Price
  • ARTL $1.16
  • SYTA $3.23
  • Analyst Decision
  • ARTL Strong Buy
  • SYTA
  • Analyst Count
  • ARTL 2
  • SYTA 0
  • Target Price
  • ARTL $5.50
  • SYTA N/A
  • AVG Volume (30 Days)
  • ARTL 33.2K
  • SYTA 240.3K
  • Earning Date
  • ARTL 03-24-2025
  • SYTA 04-07-2025
  • Dividend Yield
  • ARTL N/A
  • SYTA N/A
  • EPS Growth
  • ARTL N/A
  • SYTA N/A
  • EPS
  • ARTL N/A
  • SYTA N/A
  • Revenue
  • ARTL N/A
  • SYTA $11,988,979.00
  • Revenue This Year
  • ARTL N/A
  • SYTA $75.92
  • Revenue Next Year
  • ARTL N/A
  • SYTA $19.72
  • P/E Ratio
  • ARTL N/A
  • SYTA N/A
  • Revenue Growth
  • ARTL N/A
  • SYTA 41.59
  • 52 Week Low
  • ARTL $0.91
  • SYTA $3.04
  • 52 Week High
  • ARTL $1.70
  • SYTA $885.60
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 43.72
  • SYTA 30.99
  • Support Level
  • ARTL $1.15
  • SYTA $3.04
  • Resistance Level
  • ARTL $1.24
  • SYTA $5.40
  • Average True Range (ATR)
  • ARTL 0.10
  • SYTA 0.49
  • MACD
  • ARTL -0.02
  • SYTA -0.06
  • Stochastic Oscillator
  • ARTL 2.50
  • SYTA 8.05

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

About SYTA Siyata Mobile Inc.

Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.

Share on Social Networks: